News & Updates

Show Multimedia Only

Sexual dysfunction prevalent in breast cancer survivors

23 Feb 2026

Breast cancer survivors often experience female sexual dysfunction (FSD), which is significantly associated with disease-related factors and the lack of sexual counselling, reports a study.

Sexual dysfunction prevalent in breast cancer survivors

23 Feb 2026

3D printing enables personalization, dosing precision of ondansetron HCl dihydrate

20 Feb 2026 by

A recent study has shown the effectiveness and precision of semi-solid extrusion (SSE) 3D printing in producing various formulations of ondansetron HCl dihydrate in hospital pharmacies.

3D printing enables personalization, dosing precision of ondansetron HCl dihydrate

20 Feb 2026

Lower tolerated dose of adjuvant capecitabine seen in several TNBC patients

20 Feb 2026

Many patients with triple-negative breast cancer (TNBC) have a lower tolerated dose of capecitabine relative to the recommended adjuvant dose, a study has shown.

Lower tolerated dose of adjuvant capecitabine seen in several TNBC patients

20 Feb 2026

Evolving role of lenvatinib in management of unresectable HCC

20 Feb 2026 by

At an industry-sponsored symposium during the International Liver Cancer Association (ILCA) 2025 Annual Conference, Dr Krittiya Korphaisarn of Mahidol University, Bangkok, Thailand, reviewed systemic therapy for advanced hepatocellular carcinoma (HCC), focusing on lenvatinib as a second-line (2L) option following immunotherapy (IO). Professor Joseph Llovet of the University of Barcelona, Barcelona, Spain, and Tisch Cancer Institute at Mount Sinai, New York, US, and Professor Masatoshi Kudo of the Kindai University, Osaka, Japan, discussed the integration of systemic and locoregional treatments for intermediate HCC to optimize outcomes through multidisciplinary care.

Evolving role of lenvatinib in management of unresectable HCC

20 Feb 2026

Predictive model spots genes linked to more aggressive ATC

18 Feb 2026

A new genomic predictive model has identified mutated genes that are associated with the most aggressive anaplastic thyroid cancer (ATC), according to a study.

Predictive model spots genes linked to more aggressive ATC

18 Feb 2026

Ultraprocessed foods are the new cigarettes: study

17 Feb 2026 by

Ultraprocessed foods (UPFs) are associated with several preventable diseases and must be viewed not only through a nutritional lens but also as addictive, industrially engineered substances, which can be likened to cigarettes, suggests a recent study.

Ultraprocessed foods are the new cigarettes: study

17 Feb 2026

JAK1/2 inhibitor provides rapid and durable disease control in a patient with myelofibrosis

13 Feb 2026 by

A 67-year-old man was diagnosed with polycythaemia vera (PV) in 2005. Over the next several years, he received various cytoreductive agents, including anagrelide, pegylated interferon (IFN) and hydroxyurea.

JAK1/2 inhibitor provides rapid and durable disease control in a patient with myelofibrosis

13 Feb 2026

mOS of nearly 4 years in Tx-naïve BRAFV600E-mutant mNSCLC with combination therapy newly available in HK

13 Feb 2026

Updated results of the phase II PHAROS study of encorafenib plus binimetinib, a BRAF plus MEK inhibitor combination that has recently become available in Hong Kong, include a median overall survival (mOS) of 47.6 months in treatment-naïve patients and 22.7 months in previously treated patients with BRAF^V600E-mutant metastatic non-small-cell lung cancer (mNSCLC).

mOS of nearly 4 years in Tx-naïve BRAFV600E-mutant mNSCLC with combination therapy newly available in HK

13 Feb 2026

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

11 Feb 2026 by

Patients with potentially resectable hepatocellular carcinoma (HCC) may receive neoadjuvant nivolumab plus ipilimumab therapy, followed by surgery, to improve their survival, suggests a study.

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

11 Feb 2026

Ongoing PFS of >3 years in a patient with metastatic cholangiocarcinoma treated with durvalumab + chemotherapy

10 Feb 2026 by

The patient was a female in her early 50s, who presented was constitutional symptoms, including weight loss and fatigue, in June 2022. Baseline FDG-PET scan discovered a 9 cm highly avid liver mass, with multiple intrahepatic and lymph node metastases. The patient was put on the TOPAZ-1 regimen (durvalumab 1,500 mg on day 1 plus gemcitabine 1,000 mg/m² and cisplatin 25 mg/m²on days 1 and 8 of a 21-day cycle for a total of 8 cycles followed by durvalumab monotherapy Q4W thereafter). A follow-up FDG-PET after 8 cycles showed quiescence across all lesions, indicating complete metabolic response. Last seen in August 2025, the patient was alive and well, with an ongoing PFS of 39 months.

Ongoing PFS of >3 years in a patient with metastatic cholangiocarcinoma treated with durvalumab + chemotherapy

10 Feb 2026

News & Updates

Showing Oncology articles

Showing

Specialty:

Sexual dysfunction prevalent in breast cancer survivors

Sexual dysfunction prevalent in breast cancer survivors

3D printing enables personalization, dosing precision of ondansetron HCl dihydrate

3D printing enables personalization, dosing precision of ondansetron HCl dihydrate

Lower tolerated dose of adjuvant capecitabine seen in several TNBC patients

Lower tolerated dose of adjuvant capecitabine seen in several TNBC patients

Evolving role of lenvatinib in management of unresectable HCC

Evolving role of lenvatinib in management of unresectable HCC

Predictive model spots genes linked to more aggressive ATC

Predictive model spots genes linked to more aggressive ATC

Ultraprocessed foods are the new cigarettes: study

Ultraprocessed foods are the new cigarettes: study

JAK1/2 inhibitor provides rapid and durable disease control in a patient with myelofibrosis

JAK1/2 inhibitor provides rapid and durable disease control in a patient with myelofibrosis

mOS of nearly 4 years in Tx-naïve BRAFV600E-mutant mNSCLC with combination therapy newly available in HK

mOS of nearly 4 years in Tx-naïve BRAFV600E-mutant mNSCLC with combination therapy newly available in HK

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

Ongoing PFS of >3 years in a patient with metastatic cholangiocarcinoma treated with durvalumab + chemotherapy

Ongoing PFS of >3 years in a patient with metastatic cholangiocarcinoma treated with durvalumab + chemotherapy